担任以下学术与社会任职

中国医疗保险研究会药物经济专业委员会----副主任委员

中国药学会药物经济学专委会----副主任委员

上海市药理学会临床药理专业委员会----副主任委员

上海市药学会药物经济学专委会----副主任委员

上海市医学会临床流行病学与循证医学青年专家委员会----副主任委员

国家抗肿瘤药物临床应用监测青年专家委员会----副主任委员

《Health Economics Review》杂志副主编（SCI期刊）

科研项目：

药物经济学/循证药学

如何“安全、有效、经济”的 使用药物是我国医疗改革中提高卫生资源使用效率的一个重大课题，从药物经济学角度提供循证医学证据是解决该挑战的一个重要策略，它已成为欧美等发达国家制定药品报销目录、临床指南与临床路径等卫生管理政策的普遍依据，但包括中国在内的亚洲国家在该学科尚处于初级阶段，学科体系同欧美相比差距较大。本人2008年药学博士毕业以后在医院的日程工作中以临床疾病防治策略的经济学评价为抓手，将研究聚焦于如何将我国有限的医药卫生资源科学投入到重大疾病的预防和治疗。代表性成果归纳如下：

（1）建立了中国特色的疾病模型库与成本数据库 开展疾病管理研究需要疾病防治的临床数据支撑，逐步构建了以病种分类（ICD-9）的成本数据仓库。2015年召集四川大学华西医院等在内的全国10家知名医院成立了全国 “药物经济学研究合作联盟”，实现了数据的全国多中心采集与分析。采用决策树、Markov模型和离散事件仿真等技术，结合中国的流行病学与疾病管理数据，建立了5 大类共36 个疾病的中国卫生经济和政策模型，并系统总结了一套疾病卫生管理模型研究方法：医学问题（疾病管理）→抽象归纳（数学模型）→模型构建（程序编写）→模型验证（参数校正）→模型应用（解决问题）。

（2）系统开展了中国常见病与多发病预防与治疗的药物经济学研究

初步建立了针对微观疾病的药物经济影响分析方法 微观疾病CEA分析→宏观卫生BIA模型研究方法；

探索了特定疾病的健康结果评价方法 特定疾病生活质量量表映射到健康效用积分转换方法；

系统研究了5大类疾病55项疾病防治策略的经济学结果，提出适合中国国情的药物经济学角度决策证据15项，促进了对上述疾病管理策略的认识

论文、专利与专著：

1.Wu B, Tobe RG, Yan M, Lin H, Zhou H. Trends of global burden related to HBV and HCV from 1990 to 2019: An age-period-cohort analysis. J Med Virol. 2023;95:e28663. IF= 12.7

2.Wu B, Gu X, Zhang Q: Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small Cell Lung Cancer after Progression following First-Line EGFR TKI Therapy. Journal of Thoracic Oncology 2018, 13(2):184-193. IF= 15.609

3. Wu B, Zhang Q, Sun J: Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma. Journal for ImmunoTherapy of Cancer 2018, 6(1):124. IF= 13.751

4. Wu B, Shi L: Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. J Natl Compr Canc Netw 2020, 18(11):1528-1536. IF= 11.908

5. Hou Y, Wu B*: Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis. Cancer Communications 2020, 40(12):743-745. IF= 10.392 (通讯作者)

6. Wu B, Shi L: Frontline BRAF Testing–Guided Treatment for Advanced Melanoma in the Era of Immunotherapies: A Cost-Utility Analysis Based on Long-term Survival Data. JAMA Dermatology 2020. IF= 10.282

7. Su D, Wu B*, Shi L: Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma. JAMA Network Open 2021, 4(2):e210037. IF= 13.8 (通讯作者)

8. Wu B, Shi L: Cost-utility of ticagrelor plus aspirin in diabetic patients with stable coronary artery disease. European Heart Journal - Cardiovascular Pharmacotherapy 2020. IF= 11.17

7. Wu B, Ma F: Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer. Therapeutic Advances in Medical Oncology 2020, 12:386353104. IF= 8.168

8. Su Y, Fu J, Du J, Wu B*: First-line treatments for advanced renal-cell carcinoma with immune checkpoint inhibitors: systematic review, network meta-analysis and cost-effectiveness analysis. Therapeutic Advances in Medical Oncology 2020, 12:431402057. IF= 8.168 (通讯作者)

9. Wu B, Yang Z, Tobe RG, Wang Y: Medical therapy for preventing recurrent endometriosis after conservative surgery: a cost-effectiveness analysis. BJOG 2018, 125(4):469-477. IF= 6.531

10. Wu B, Lu S: The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis. Translational lung cancer research 2020, 9(5):1770-1784. IF= 6.498

11. Wu B, Gao J, Wang MW: Development of a complex scintillation proximity assay for high-throughput screening of PPARgamma modulators. ACTA PHARMACOLOGICA SINICA 2005, 26(3):339-344. IF= 6.150

12. Hou X, Wan X, Wu B*: Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China. Frontiers in Pharmacology 2019, 10:480. IF= 5.810 (通讯作者)

13. Chai QQ, Du JY, Zhu J, Wu B*: The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review. Frontiers in Pharmacology 2019, 10:1260. IF= 5.810 (通讯作者)

14. Su D, Wu B*, Shi L: Cost-Effectiveness of Genomic Test-Directed Olaparib for Metastatic Castration-Resistant Prostate Cancer. Frontiers in Pharmacology 2021, 11:2436. IF= 5.810 (通讯作者)

15. Wu B, Zhu JS, Zhang Y, Shen WM, Zhang Q: Predictive value of MTT assay as an in vitro chemosensitivity testing for gastric cancer: one institution's experience. World J Gastroenterol 2008, 14(19):3064-3068. IF= 5.742

16. Wu B, Li T, Chen H, Shen J: Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis. VALUE IN HEALTH 2010, 13(5):592-600. IF= 5.725

17. Gu X, Zhang Q, Chu Y, Zhao Y, Zhang Y, Kuo D, Su B, Wu B*: Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China. LUNG CANCER 2019, 127(1):84-89. IF= 5.705 (通讯作者)

18. Wu B, Wang Z, Zhang Q: Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis. INFLAMMATORY BOWEL DISEASES 2018, 24(11):2291-2302. IF= 5.325

19. Lu S, Ye M, Ding L, Tan F, Fu J, Wu B*: Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China. Oncotarget 2017, 8(6):9996-10006. IF= 5.168 (通讯作者)

20. Wu B, Yao Y, Zhang K, Ma X: RAS testing and cetuximab treatment for metastatic colorectal cancer: a cost-effectiveness analysis in a setting with limited health resources. Oncotarget 2017, 8(41):71164-71172. IF= 5.168

21. Wu B, Gu X, Zhang Q, Xie F: Cost‐Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR‐Mutation‐Positive Non‐Small Cell Lung Cancer. The Oncologist 2018, 24(3):349-357. IF= 5.025

22. Bai Y, Ye M, Cao H, Ma X, Xu Y, Wu B*: Economic evaluation of radiotherapy for early breast cancer after breast-conserving surgery in a health resource-limited setting. Breast Cancer Res Treat 2012, 136(2):547-557. IF= 4.872 (通讯作者)

23. Wu B, Song Y, Leng L, Bucala R, Lu LJ: Treatment of moderate rheumatoid arthritis with different strategies in a health resource-limited setting: a cost-effectiveness analysis in the era of biosimilars. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2015, 33(1):20-26. IF= 4.473

24. Zhu J, Li T, Wang X, Ye M, Cai J, Xu Y, Wu B*: Gene-guided gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive non-small cell lung cancer: an economic analysis. BMC CANCER 2013, 13:39. IF= 4.430 (通讯作者)

25. Wu B, Li T, Cai J, Xu Y, Zhao G: Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy. BMC CANCER 2014, 14:984. IF= 4.430

26. Wu B, Zhang S, Lin H, Mou S: Prevention of renal failure in Chinese patients with newly diagnosed type 2 diabetes: A cost-effectiveness analysis. Journal of Diabetes Investigation 2018, 9(1):152-161. IF= 4.232

27. Chai Q, Shen Y, Du J, Zhu J, Wu B*: Economic burden of patients with advanced non-small-cell lung cancer receiving nivolumab versus chemotherapy in China. Immunotherapy 2020, 12(4):245-254. IF= 4.196 (通讯作者)

28. Jing M, Xu W, Wu B*: The Cost-Effectiveness of Lifestyle Interventions for Preventing Diabetes in a Health Resource-Limited Setting. Journal of Diabetes Research 2020, 2020:7410797. IF= 4.011 (通讯作者)

29. Wu B, Wan X, Ma J: Cost-effectiveness of prevention and management of diabetic foot ulcer and amputation in a health resource-limited setting. Journal of Diabetes 2018, 10(4):320-327. IF= 4.006

30. Chen R, Wu B*: Cost-effectiveness of intravitreal conbercept versus other treatments for wet age-related macular degeneration. Ann Transl Med 2020, 8(15):939. IF= 3.932 (通讯作者)

31. Wu B, Wang Z, Zhang Q: Age at Initiation and Frequency of Screening to Prevent Esophageal Squamous Cell Carcinoma in High-risk Regions: an Economic Evaluation. Cancer Prev Res (Phila) 2020, 13(6):543-550. IF= 3.866

32. Yan X, Gu X, Xu Z, Lin H, Wu B*: Cost-Effectiveness of Different Strategies for the Prevention of Venous Thromboembolism After Total Hip Replacement in China. ADVANCES IN THERAPY 2017, 2(34):466-480. IF= 3.845 (通讯作者)

33. Li T, Wan X, Ma J, Wu B*: Cost-Effectiveness of Primary Prevention with Statin Treatment for Chinese Patients with Type 2 Diabetes. ADVANCES IN THERAPY 2018, 35(12):2214-2223. IF= 3.845

34. Du J, Wang Z, Wu B*: Expanding Antiviral Prophylaxis During Pregnancy to Prevent Perinatal Hepatitis B Virus Infection: A Cost-effectiveness Study. Open Forum Infectious Diseases 2020, 7(5):a137. IF= 3.835 (通讯作者)

35. Wu B, Kun L, Liu X, He B: Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting. Cardiovasc Drugs Ther 2014, 28(1):87-98. IF= 3.727

36. Zhao D, Gai Tobe R, Cui M, He J, Wu B*: Cost-effectiveness of a 23-valent pneumococcal polysaccharide vaccine immunization programme for the elderly in Shanghai, China. VACCINE 2016, 34(50):6158-6165. IF= 3.641 (通讯作者)

39. Ye M, Lu J, Yang F, Wu B*: Economic Evaluation of Letrozole for Early Breast Cancer in a Health Resource-Limited Setting. Biomed Research International 2018, 2018:1-8. IF= 3.411 (通讯作者)

40. Wang Z, Zhang Q, Wu B*: Development of an Empirically Calibrated Model of Esophageal Squamous Cell Carcinoma in High-Risk Regions. Biomed Research International 2019, 2019:1-9. IF= 3.411 (通讯作者)

41. Zhu J, He W, Ye M, Fu J, Chu Y, Zhao Y, Zhang Y, Kuo D, Wu B*: Cost–effectiveness of afatinib and erlotinib as second-line treatments for advanced squamous cell carcinoma of the lung. Future Oncology 2018, 14(27):2833-2840. IF= 3.404 (通讯作者)

42. Wu B, Zhang Q, Shen W, Zhu J: Anti-proliferative and chemosensitizing effects of luteolin on human gastric cancer AGS cell line. MOLECULAR AND CELLULAR BIOCHEMISTRY 2008, 313(1-2):125-132. IF= 3.396

43. Wu B, Chen H, Shen J, Ye M: Cost-Effectiveness of Adding Rh-Endostatin to First-Line Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer in China. CLINICAL THERAPEUTICS 2011, 33(10):1446-1455. IF= 3.393

44. Wu B, Ye M, Chen H, Shen JF: Costs of Trastuzumab in Combination With Chemotherapy for HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: An Economic Evaluation in the Chinese Context. CLINICAL THERAPEUTICS 2012, 34(2):468-479. IF= 3.393

45. Cheng H, Wan X, Ma J, Wu B*: Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Insulin-naive Chinese Patients With Type 2 Diabetes. CLINICAL THERAPEUTICS 2019, 41(3):445-455. IF= 3.393 (通讯作者)

46. Wu B, Dong B, Xu Y, Zhang Q, Shen J, Chen H, Xue W: Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting. PLoS One 2012, 7(3):e32530. IF= 3.240

47. Wu B, Miao Y, Bai Y, Ye M, Xu Y, Chen H, Shen J, Qiu Y: Subgroup economic analysis for glioblastoma in a health resource-limited setting. PLoS One 2012, 7(4):e34588. IF= 3.240

48. Wu B, Wilson A, Wang FF, Wang SL, Wallace DJ, Weisman MH, Lu LJ: Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china. PLoS One 2012, 7(10):e47373. IF= 3.240

49. Wei BJ, Chen YJ, Yu L, Wu B*: Periodontal disease and risk of preeclampsia: a meta-analysis of observational studies. PLoS One 2013, 8(8):e70901. IF= 3.240 (通讯作者)

50. Wu B, Wu H, Liu X, Lin H, Li J: Ranibizumab versus bevacizumab for ophthalmic diseases related to neovascularisation: a meta-analysis of randomised controlled trials. PLoS One 2014, 9(7):e101253. IF= 3.240

51. Che D, Zhou H, Li T, Wu B*: Duration and intensity of fluconazole for prophylaxis in preterm neonates: a meta-analysis of randomized controlled trials. BMC INFECTIOUS DISEASES 2016, 16(1):1-7. IF= 3.090 (通讯作者)

52. Li T, Liu M, Ben H, Xu Z, Zhong H, Wu B*: Clopidogrel versus aspirin in patients with recent ischemic stroke and established peripheral artery disease: an economic evaluation in a Chinese setting. Clin Drug Investig 2015, 35(6):365-374. IF= 2.859 (通讯作者)

53. Yan X, Gu X, Zhou L, Lin H, Wu B*: Cost Effectiveness of Apixaban and Enoxaparin for the Prevention of Venous Thromboembolism After Total Knee Replacement in China. CLINICAL DRUG INVESTIGATION 2016, 36(12):1001-1010. IF= 2.859 (通讯作者)

54. Liu Y, Wang Z, Tobe RG, Lin H, Wu B*: Cost Effectiveness of Daclatasvir Plus Asunaprevir Therapy for Chinese Patients with Chronic Hepatitis C Virus Genotype 1b. CLINICAL DRUG INVESTIGATION 2018, 38(5):427-437. IF= 2.859 (通讯作者)

55. Wu B, Tobe RG, Liu Y, He B: Health Economic Analysis of Antiplatelet Therapy for Acute Coronary Syndromes in the Context of Five Eastern Asian Countries. Clin Drug Investig 2018, 38(7):621-630. IF= 2.859

56. Fu J, Liu Y, Lin H, Wu B*: Economic Evaluations of Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia in Middle- and High-Income Countries: A Systematic Review. CLINICAL DRUG INVESTIGATION 2018, 38(12):1167-1178. IF= 2.859 (通讯作者)

57. Bao Y, Zhao G, Qu S, Xiong T, Yao X, Wu B*: A Caprini Risk Score-Based Cost-Effectiveness Analysis of Enoxaparin for the Thromboprophylaxis of Patients After Nonorthopedic Surgery in a Chinese Healthcare Setting. Clin Drug Investig 2020, 40(2):161-171. IF= 2.859 (通讯作者)

58. Li H, Lai L, Wu B*: Cost Effectiveness of Ceritinib and Alectinib Versus Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-small-cell Lung Cancer. Clin Drug Investig 2020, 40(2):183-189. IF= 2.859 (通讯作者)

59. Du J, Wu B*: New Oral Anticoagulants for Thromboprophylaxis in Patients with Cancer Receiving Chemotherapy: An Economic Evaluation in a Chinese Setting. Clin Drug Investig 2020, 40(7):653-663. IF= 2.859 (通讯作者)

60. Wu B, Shen J, Cheng H: Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China. BMC HEALTH SERVICES RESEARCH 2012, 12:385. IF= 2.655

61. Che D, Zhou H, He J, Wu B*: Modeling the impact of the 7-valent pneumococcal conjugate vaccine in Chinese infants: an economic analys (通讯作者)is of a compulsory vaccination. BMC HEALTH SERVICES RESEARCH 2014, 14:56. IF= 2.655

62. Wu B, Wang Z, Xie Q: Cost-effectiveness of novel regimens for Chinese patients with chronic hepatitis C. CURRENT MEDICAL RESEARCH AND OPINION 2018, 35(5):847-857. IF= 2.580

63. Lu S, Zhang J, Ye M, Wang B, Wu B*: Economic analysis of ALK testing and crizotinib therapy for advanced non-small-cell lung cancer. PHARMACOGENOMICS 2016, 17(9):985-994. IF= 2.533 (通讯作者)

64. Nian H, Wan X, Ma J, Jie F, Wu B*: Economic evaluation of dapagliflozin versus metformin in Chinese patients whose diabetes is inadequately controlled with diet and exercise. Cost Effectiveness and Resource Allocation 2020, 18(1):12. IF= 2.532 (通讯作者)

65. Zhou H, Lu Y, Wu B*, Che D: Cost-effectiveness of omalizumab for the treatment of inadequately controlled severe allergic asthma in Chinese children. JOURNAL OF ASTHMA 2020, 57(1):87-94. IF= 2.515 (通讯作者)

66. Zheng Y, Tang K, Ye L, Ai Z, Wu B*: Mapping the neck disability index to SF-6D in patients with chronic neck pain. Health Qual Life Outcomes 2016, 14:21. IF= 2.318 (通讯作者)

67. Bai Y, Xu Y, Wu B*: Cost-Effectiveness and Budget Impact Analysis of Apatinib for Advanced Metastatic Gastric Cancer from the Perspective of Health Insurance System. Gastroenterol Res Pract 2017, 2017:2816737. IF= 2.260 (通讯作者)

68. Zhou H, Lu Y, Wu B*, Che D: Cost-effectiveness of Oral Regimens for Adolescents With Chronic Hepatitis C Virus Infection. PEDIATRIC INFECTIOUS DISEASE JOURNAL 2020, 39(6):e59-e65. IF= 2.129 (通讯作者)

69. Wu B, Li J, Lin H, Wu H: Different Strategies for the Treatment of Age-Related Macular Degeneration in China: An Economic Evaluation. Journal of Ophthalmology 2016, 2016:12. IF= 1.909

70. Wu B, Li J, Wu H: Strategies to Screen for Diabetic Retinopathy in Chinese Patients with Newly Diagnosed Type 2 Diabetes: A Cost-Effectiveness Analysis. Medicine (Baltimore) 2015, 94(45):e1989. IF= 1.889

71. Wu B, Liu M, Li T, Lin H, Zhong H: An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China: A CHEERS-compliant article. MEDICINE 2017, 96(29). IF= 1.889

72. Wu B, Lin H, Tobe RG, Zhang L, He B: Ticagrelor versus clopidogrel in East-Asian patients with acute coronary syndromes: a meta-analysis of randomized trials. J Comp Eff Res 2018, 7(3):281-291. IF= 1.744

73. Wu B, Ma J, Zhang S, Zhou L, Wu H: Development and validation of a Health Policy Model of Type 2 diabetes in Chinese setting. Journal of Comparative Effectiveness Research 2018, 7(8):749-763. IF= 1.744

74. Zhou H, He J, Wu B*, Che D: Cost-effectiveness analysis of routine 13-valent pneumococcal conjugate vaccinations in Chinese infants. Hum Vaccin Immunother 2018, 14(6):1444-1452. IF= 3.452 (通讯作者)